294 related articles for article (PubMed ID: 19324253)
1. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.
Jeong YH; Lee SW; Choi BR; Kim IS; Seo MK; Kwak CH; Hwang JY; Park SW
J Am Coll Cardiol; 2009 Mar; 53(13):1101-9. PubMed ID: 19324253
[TBL] [Abstract][Full Text] [Related]
2. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
[TBL] [Abstract][Full Text] [Related]
3. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
Hwang SJ; Jeong YH; Kim IS; Park KS; Kang MK; Koh JS; Park JR; Park Y; Koh EH; Kwak CH; Hwang JY; Kim S
Circ Cardiovasc Interv; 2010 Oct; 3(5):450-9. PubMed ID: 20823393
[TBL] [Abstract][Full Text] [Related]
5. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
[TBL] [Abstract][Full Text] [Related]
6. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
7. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study.
Woo JS; Kim W; Lee SR; Jung KH; Kim WS; Lew JH; Lee TW; Lim CK
Am Heart J; 2011 Dec; 162(6):1018-25. PubMed ID: 22137075
[TBL] [Abstract][Full Text] [Related]
8. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Nakagawa I; Wada T; Park HS; Nishimura F; Yamada S; Nakagawa H; Kichikawa K; Nakase H
J Vasc Surg; 2014 Mar; 59(3):761-7. PubMed ID: 24239116
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
10. Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
Panchal HB; Shah T; Patel P; Albalbissi K; Molnar J; Coffey B; Khosla S; Ramu V
J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):533-43. PubMed ID: 23872509
[TBL] [Abstract][Full Text] [Related]
11. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
[TBL] [Abstract][Full Text] [Related]
12. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.
Ha SJ; Kim SJ; Hwang SJ; Woo JS; Kim W; Kim WS; Kim KS; Kim MK
Coron Artery Dis; 2013 Dec; 24(8):690-7. PubMed ID: 24152567
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
[TBL] [Abstract][Full Text] [Related]
14. Loading effect of 200 mg cilostazol on platelet inhibition in patients undergoing percutaneous coronary intervention.
Jin EZ; Yu LH; Li XQ
Int Heart J; 2012; 53(1):1-4. PubMed ID: 22398668
[TBL] [Abstract][Full Text] [Related]
15. [The effects of post coronary stenting triple antiplatelet therapies on platelet functions].
Han YL; Su QF; Li Y; Kang J; Yan CH; Wang SL
Zhonghua Nei Ke Za Zhi; 2006 Aug; 45(8):635-8. PubMed ID: 17074146
[TBL] [Abstract][Full Text] [Related]
16. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
[TBL] [Abstract][Full Text] [Related]
17. Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Cuisset T; Quilici J; Grosdidier C; Fourcade L; Gaborit B; Pankert M; Molines L; Morange PE; Bonnet JL; Alessi MC
Am J Cardiol; 2011 Nov; 108(10):1411-6. PubMed ID: 21872198
[TBL] [Abstract][Full Text] [Related]
18. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
[TBL] [Abstract][Full Text] [Related]
19. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
[TBL] [Abstract][Full Text] [Related]
20. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study.
Collet JP; Silvain J; Landivier A; Tanguy ML; Cayla G; Bellemain A; Vignolles N; Gallier S; Beygui F; Pena A; Montalescot G
Circulation; 2008 Sep; 118(12):1225-33. PubMed ID: 18765393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
